Market Cap€528.6m

Last Close €47.85

Formycon is a biotechnology company developing biosimilars. The main lead is FYB201, a Lucentis biosimilar candidate that has completed Phase III and is entering regulatory review. FYB203 is an Eylea candidate biosimilar in preclinical. They are both out-licensed. FYB202, a biosimilar candidate of Stelara, is being developed in a joint venture.

More Formycon content >

Investment summary

Formycon progressed all key projects in H121. FYB201 (partnered with Bioeq) is a Lucentis biosimilar to treat neovascular age-related macular degeneration (nAMD). The US FDA is reviewing the BLA with an August 2022 decision due; the European EMA review should complete in mid-2021. FYB201 will be marketed by Teva in Europe and by Coherus in the US. FYB202 (a Stelara biosimilar in a joint venture with Aristo Pharma) is waiting for its Phase III readout in psoriasis. FYB203 (an Eylea biosimilar partnered with Klinge) is in late Phase III in nAMD. FYB207 is a novel COVID-19 therapy with a €12.7m grant and H122 Phase I/IIa trials planned. Formycon had €33.6m cash on 30 June 2021. H121 revenue was €20.3m (H120: €16.5m). The loss rose to €10.2m (FY20: loss of €5.9m) due to investment into unpartnered projects.

Content on Formycon
Formycon – H121 update: Future markets take shape
Healthcare | Update | 14 October 2021
View more
Register to receive research on Formycon as it is published
Share price graph
Price performance
Actual (15.5) (11.4) (22.8)
Relative* (16.3) (12.1) (31.2)
52-week high/low €78.6/€44.0
*% relative to local index
Key management
Dr Carsten Brockmeyer CEO
Dr Nicolas Combé CFO
Dr Stefan Glombitza COO